Association of serum uric acid and incident nonspine fractures in elderly men: The Osteoporotic Fractures in Men (MrOS) study

Journal of Bone and Mineral Research

Volumn 29, Issue 7, 2014, Pages 1701-1707

  Lane, Nancy E ^a   Parimi, Neeta ^b   Lui, Li Yung ^b   Wise, Barton L ^a   Yao, Wei ^a   Lay, Yu An Evan ^a   Cawthon, Peggy M ^b   Orwoll, Eric ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

AGING; DXA < ANALYSIS QUANTITATION OF BONE; EPIDEMIOLOGY

Indexed keywords

PARATHYROID HORMONE; PHOSPHORUS; URIC ACID; VITAMIN D; ALLOPURINOL;

AGE DISTRIBUTION; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; BONE DENSITY; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; DISEASE ASSOCIATION; FRAGILITY FRACTURE; GERIATRIC PATIENT; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PHYSICAL ACTIVITY SCALE FOR THE EDERLY SCORE; PROSPECTIVE STUDY; RACE DIFFERENCE; RISK ASSESSMENT; URIC ACID BLOOD LEVEL; WALKING SPEED; BLOOD; COMPLICATION; GOUT; INCIDENCE; OSTEOPOROTIC FRACTURES; PATHOPHYSIOLOGY; UNITED STATES;

AGED; ALLOPURINOL; BONE DENSITY; COHORT STUDIES; GOUT; HIP FRACTURES; HUMANS; INCIDENCE; MALE; OSTEOPOROTIC FRACTURES; UNITED STATES; URIC ACID;

EID: 84902317052     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2164     Document Type: Article

References (42)

1. Mandell BF., Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med. 2008; 75: S5-8.
2. Nabipour I, Sambrook PN, Blyth FM, et al. Serum uric acid is associated with bone health in older men: a cross-sectional population based study. J Bone Miner Res. 2011; 26 (5): 955-64.
3. Edwards NL., The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol. 2009; 21: 132-7.
4. Holme I, Aasteveit AH, Hammar N, Jungner I, Walldius G., Uric acid and risk of myocardial infarction, stroke, and congestive heart failure in 417,734 men and women in the Apolipoprotein Mortality Risk study (AMORIS). J Intern Med. 2009; 266: 558-60.
5. Kim SY, Guevera JP, Kim KM, Choi HK, Heitjan DF, Albert DA., Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009; 61: 885-92.
6. Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC., High uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008; 31: 361-2.
7. Oda E, Kawai R, Sukumaran V, Watanabe K., Uric acid is positively associated with metabolic syndrome but negatively associated with diabetes in Japanese men. Intern Med. 2009; 48: 1785-91.
8. Glantzounic GK, Tsimoyiannis EC, Kappas AM, Galaris DA., Uric acid and oxidative stress. Curr Pharm Des. 2005; 11: 724-8.
9. Ames BN, Cathart R, Schwiers E, Hochstein P., Uric acid provides an antioxidant defense in humans against oxidant and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981; 78: 6858-62.
10. Alonso A, Garcia-Rodriguez LA, Logroscino G, Herman MA., Gout and risk of Parkinson's disease: a cohort study. Neurology. 2007; 69: 1696-700.
11. Chen H, Mosley TH, Alonso A, Huang X., Plasma urate and Parkinson's disease. Am J Epidemiol. 2009; 169: 1064-9.
12. Ahn SH, Lee SH, Kim B-J, et al. Higher serum uric acid is associated with higher bone mass, lower bone turnover and lower prevalence of vertebral fracture in health postmenopausal women. Osteoporos Int. 2013; 24: 2961-70.
13. Sugiura M, Nakamura M, Ogawa K, Iloma Y, Ando F, Yano M., Bone mineral density in post-menopausal female subjects is associated with serum antioxidants carotenoids. Osteoporos Int. 2008; 19: 211-9.
14. Sritara C, Ongphiphadhanakui B, Chailurkit L, Yamwong S, Ratanachaiwong W, Sritara P., Serum uric acid levels in relation to bone related phenotypes in men and women. J Clin Densitom. 2013; 16: 336-40.
15. Makovey J, Macara M, Chen JS, et al. Serum uric acid plays a protective role for bone loss in peri and postmenopausal women: a longitudinal study. Bone. 2013; 52: 400-6.
16. Maggio D, Barabani M, Pierandrei M, et al. Marked decrease in plasma antioxidants in aged osteoporotic women; results of a cross-sectional study. J Clin Endocrinol Metab. 2003; 88: 1523-7.
17. Sendur OF, Turan Y, Tastaban E, Serter M., Antioxidant status in patients with osteoporosis: a controlled study. Joint Bone Spine. 2009; 76: 514-8.
18. Orwoll E, Blank JB, Barrett-Connor E, et al. Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study-a large observational study of the determinants of fracture in older men. Contemp Clin Trials. 2005; 26 (5): 569-85.
19. Blank JB, Cawthon PM, Carrion-Petersen ML, et al. Overview of recruitment for the osteoporotic fractures in men study (MrOS). Contemp Clin Trials. 2005; 26 (5): 557-68.
20. Lewis CE, Ewing SK, Taylor BC, et al. Predictors of nonspine fracture in elderly men: the MrOS study. J Bone Miner Res. 2007; 22 (2): 211-9.
21. Singh RJ, Taylor RL, Reddy GS, Grebe SK., C-3 epimers can account for a significant proportion of total circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D status. JCEM. 2006; 91 (8): 3055-61.
22. Erlandsen EJ, Randers E, Kristensen JH., Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest. 1999; 59 (1): 1-8.
23. Inker LA, Eckfeldt J, Levey AS, et al. Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values. Am J Kidney Dis. 2011; 58: 682-4.
24. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008; 51: 395-406.
25. Inker LA, Schmid CH, Tighiouart H, et al. CKD-EPI investigators. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012; 5; 367 (1): 20-9.
26. Washburn RA, Ficker JL., Physical Activity Scale for the Elderly (PASE): the relationship with activity measured by a portable accelerometer. J Sports Med Phys Fitness. 1999; 39: 336-40.
27. Ensrud KE, Taylor BC, Paudel ML, et al. Serum 25-hydroxyvitamin D levels,rate of hip bone loss in older men. JCEM. 2009; 94: 2773-80.
28. Lee CG, Boyko EJ, Nielson CM, et al. Mortality risk in older men associated with changes in weight, lean mass, and fat mass. J Am Geriatr Soc. 2011; 59: 233-40.
29. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001; 56: M146-56.
30. Cawthon PM, Marshall LM, Michael Y, et al. Frailty in older men: prevalence, progression, and relationship with mortality. J Am Geriatr Soc. 2007; 55: 1216-23.
31. Ware JE, Kosinski M, Keller SD., SF-12: How to score the SF-12 physical and mental health summary scores. 3rd ed. Lincoln, RI: QualityMetric, Inc; 1998.
32. Yoneda M, Takatsuki K, Tomita A., Parathyroid function and uric acid metabolism. Nippon Naibunpi Gakkai Zasshi. 1983; 59: 1738-51.
33. Valdemarsson S, Lindblom P, Bergenfelz A., Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment. J Intern Med. 1998; 244: 241-9.
34. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344 (19): 1434-41.
35. Masseoud D, Rottt K, Liu-Bryan R, Agudelo C., Overview of hyperuricemia and gout. Curr Pharm Des. 2005; 11: 4117-24.
36. Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA., Uric acid and oxidative stress. Curr Pharm Des. 2005; 11: 4145-51.
37. Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G., The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta. 2008; 392: 1-7.
38. Duan W, Ladenheim B, Cutler RG, et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem. 2002; 80: 101-10.
39. Spitsin S, Hooper DC, Leist T, et al. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler. 2001; 7: 313-9.
40. Scott GS, Spitsin SV, Kean RB, et al. Therapeutic intervention in experimental allergic encephalitis by administration of uric acid precursors. Proc Natl Acad Sci USA. 2002; 99: 16303-8.
41. Shen H, Chen GJ, Harvey BK, et al. Inosine reduces ischemic brain injury in rats. Stroke. 2005; 36: 654-9.
42. Sánchez-Lozada LG, Lanaspa MA, Cristóbal-García M, et al. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol. 2012; 121 (3-4): 71-8.